CL2013001054A1 - Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others. - Google Patents
Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others.Info
- Publication number
- CL2013001054A1 CL2013001054A1 CL2013001054A CL2013001054A CL2013001054A1 CL 2013001054 A1 CL2013001054 A1 CL 2013001054A1 CL 2013001054 A CL2013001054 A CL 2013001054A CL 2013001054 A CL2013001054 A CL 2013001054A CL 2013001054 A1 CL2013001054 A1 CL 2013001054A1
- Authority
- CL
- Chile
- Prior art keywords
- type
- diabetes
- cyanopyrazoles
- hyperlipidemia
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41644110P | 2010-11-23 | 2010-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013001054A1 true CL2013001054A1 (en) | 2013-09-27 |
Family
ID=45418722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013001054A CL2013001054A1 (en) | 2010-11-23 | 2013-04-16 | Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others. |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP2643310A1 (en) |
JP (1) | JP2013543885A (en) |
KR (1) | KR20130083915A (en) |
CN (1) | CN103298801A (en) |
AP (1) | AP2013006809A0 (en) |
AR (1) | AR088121A1 (en) |
AU (1) | AU2011333427A1 (en) |
BR (1) | BR112013011865A2 (en) |
CA (1) | CA2814231A1 (en) |
CL (1) | CL2013001054A1 (en) |
CO (1) | CO6801716A2 (en) |
CR (1) | CR20130139A (en) |
CU (1) | CU20130059A7 (en) |
DO (1) | DOP2013000102A (en) |
EA (1) | EA201370118A1 (en) |
EC (1) | ECSP13012630A (en) |
GT (1) | GT201300135A (en) |
MA (1) | MA34805B1 (en) |
MX (1) | MX2013004083A (en) |
NI (1) | NI201300044A (en) |
PE (1) | PE20140409A1 (en) |
SG (1) | SG189830A1 (en) |
TW (1) | TWI433843B (en) |
UY (1) | UY33742A (en) |
WO (1) | WO2012069948A1 (en) |
ZA (1) | ZA201302362B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
JP2017119628A (en) * | 2014-05-09 | 2017-07-06 | 日産化学工業株式会社 | Substituted azole compound and therapeutic agent for diabetes |
CN104892517A (en) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | Hydrazine compound, method for preparing same and application of hydrazine compound |
CN104610151A (en) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof |
CN104592120A (en) * | 2015-02-13 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof |
JP6850300B2 (en) | 2016-02-18 | 2021-03-31 | シンジェンタ パーティシペーションズ アーゲー | Pesticide active pyrazole derivative |
CN106631992B (en) * | 2017-01-05 | 2019-01-18 | 桑迪亚医药技术(上海)有限责任公司 | A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0814294A2 (en) * | 2007-07-19 | 2015-02-03 | Metabolex Inc | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders. |
ES2543358T3 (en) * | 2008-03-31 | 2015-08-18 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds and uses thereof |
EA020106B1 (en) * | 2009-06-05 | 2014-08-29 | Пфайзер Инк. | L-(piperidin-4-yl)pyrazole derivatives as gpr119 modulators |
-
2011
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/en not_active Application Discontinuation
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/en not_active Application Discontinuation
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/en not_active IP Right Cessation
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en active Application Filing
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 MA MA35928A patent/MA34805B1/en unknown
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/en active Pending
- 2011-11-09 EA EA201370118A patent/EA201370118A1/en unknown
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/en unknown
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/en unknown
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/en active Pending
- 2011-11-21 UY UY0001033742A patent/UY33742A/en unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/en not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/en not_active IP Right Cessation
-
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/en unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/en unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/en unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/en unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/en unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/en unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/en unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2011333427A1 (en) | 2013-04-11 |
EA201370118A1 (en) | 2013-12-30 |
BR112013011865A2 (en) | 2016-08-23 |
KR20130083915A (en) | 2013-07-23 |
CR20130139A (en) | 2013-06-28 |
TWI433843B (en) | 2014-04-11 |
TW201300373A (en) | 2013-01-01 |
NI201300044A (en) | 2013-08-01 |
DOP2013000102A (en) | 2013-07-15 |
AP2013006809A0 (en) | 2013-04-30 |
CU20130059A7 (en) | 2013-06-28 |
SG189830A1 (en) | 2013-06-28 |
CA2814231A1 (en) | 2012-05-31 |
CN103298801A (en) | 2013-09-11 |
GT201300135A (en) | 2015-02-19 |
PE20140409A1 (en) | 2014-03-23 |
UY33742A (en) | 2012-06-29 |
EP2643310A1 (en) | 2013-10-02 |
JP2013543885A (en) | 2013-12-09 |
WO2012069948A1 (en) | 2012-05-31 |
AR088121A1 (en) | 2014-05-14 |
MX2013004083A (en) | 2013-06-13 |
ZA201302362B (en) | 2014-06-25 |
MA34805B1 (en) | 2014-01-02 |
ECSP13012630A (en) | 2013-07-31 |
CO6801716A2 (en) | 2013-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013001054A1 (en) | Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others. | |
CL2008002110A1 (en) | PROCEDURE FOR THE MODULATION OF THE RECEPTOR COUPLED TO PROTEIN G GPR119 TO ADMINISTER A COMPOUND DERIVED FROM PIRIDINONE AND OPTIONALLY AN OPTIONAL THERAPEUTIC AGENT TO TREAT MELLITUS DIABETES. | |
EA201001329A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
SMT201600216B (en) | OCTAIDROPIRROL [3,4.C] PIRROLS DISTRIBUTED AS MODULATORS OF OREXINA RECEPTOR | |
CL2013000716A1 (en) | A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes. | |
CL2013000787A1 (en) | Compounds derived from substituted fused benzamide, bradykinin receptor modulators; Pharmaceutical composition, useful in the treatment of acute, visceral, neuropathic pain, skin inflammation, among others. | |
EA201391764A1 (en) | GLP-1 / GLUCAGON LONG-TERM RECEPTOR AGONISTS | |
EA201001332A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
CL2013003598A1 (en) | Compounds derived from benzooxazepinone, sodium channel modulators; pharmaceutical composition comprising them; and its use in the treatment of selected diseases of arrhythmias, heart failure, angina, myocardial infarction, diabetes, among others | |
CL2010001496A1 (en) | Compounds derived from (pyridin- or pyrimidin-) piperidine, gpr119 agonists; pharmaceutical composition; and its use for the treatment of type I diabetes, type II diabetes and related diseases such as metabolic syndrome, dyslipidemia and insulin resistance. | |
CL2008000198A1 (en) | COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS. | |
CL2013000714A1 (en) | Compounds derived from piperidinyl substituted lactams, modulators of gpr119; Preparation process; pharmaceutical composition that includes them; treatment method; and use of the compound to treat diseases such as type 2 diabetes, metabolic syndrome, dyslipidemia, hypertension and schizophrenia, among others. | |
BRPI1008971A2 (en) | methods for preparing a conditionally active biological protein, and a conditionally active biological response modifier, conditionally active biological protein, and pharmaceutical composition | |
CL2008000690A1 (en) | COMPOUNDS DERIVED FROM INDOL-3-PROPIONIC ACID; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA, HYPERTENSION; AMONG OTHER. | |
EA201001330A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
BRPI1012116A2 (en) | pharmaceutical composition for the treatment of heart disease | |
CL2007002348A1 (en) | HETEROCICLICAL COMPOUNDS, MODULATORS OF THE ACTIVITY OF ESTEAROIL-COA-DESATURASA; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF DISEASES SUCH AS DIABETES, DISLIPIDEMIAS, OBESITY, ANOREXIA AND ACNE. | |
CL2013002414A1 (en) | Compounds derived from cyclic azabenzimidazole, activators of amp-activated protein kinase; pharmaceutical composition that includes them; and its use for treatment or disease such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and hypertension. | |
CL2013003372A1 (en) | Compounds derived from spiro- [1,3] -oxacins and spiro- [1,4] -oxacepins, inhibitors of bace1 and / or bace2; pharmaceutical composition; procedure to prepare them; and its use in the treatment and / or prophylaxis of Alzheimer's disease and diabetes. | |
CL2013002053A1 (en) | Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct | |
EA201290964A1 (en) | Peptide Conjugates of GLP-1 Receptor Agonists and Their Use | |
BR112012004333A2 (en) | compound, pharmaceutical composition, and method for treating or preventing a disease or disorder. | |
CL2013001104A1 (en) | Pharmaceutical composition comprising a sglt2 inhibitor and an insulin; and use to treat a disease or condition such as diabetes mellitus, diabetes mellitus type 1 and 2, among others. | |
BRPI0915382A2 (en) | compound, pharmaceutical composition, and method for treating a disease or disorder. | |
BRPI0813456A2 (en) | COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A MAMMAL WITH A DISORDER AND DISEASE |